High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma
DOI: https://doi.org/10.2147/PGPM.S382843
2023-01-07
Pharmacogenomics and Personalized Medicine
Abstract:Xuegang Wang, 1, &ast Weiquan Li, 2, &ast Ning Lou, 3, &ast Weiwei Han, 3 Bo Hai, 2 Wen Xiao, 2 Xiaoping Zhang 2 1 Department of Urology, The First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, People's Republic of China; 2 Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 3 Department of Urology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen Xiao; Bo, Hai, Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province, 430022, People's Republic of China, Tel +86-17088353610, Fax +86 85776343, Email ; Background: Invasion and metastasis led to poor prognosis and death of clear cell renal cell carcinoma (ccRCC) patients. The deoxynucleotidyl transferase terminal interacting protein 1 (DNTTIP1) was reported to promote multiple tumor progression. However, there is no research about DNTTIP1 in ccRCC. Methods: Kaplan–Meier survival analysis, multivariate analysis demonstrated the prognostic indicator in overall survival (OS) and disease-free survival (DFS) of ccRCC with DNTTIP1 expression in the Cancer Genome Atlas Kidney Clear Cell Carcinoma (TCGA-KIRC). Receiver operator characteristic (ROC) curve analyzed diagnostic ability of DNTTIP1 in TCGA-KIRC and validation dataset. The quantitative real-time polymerase chain reaction (qRT-PCR) detected the DNTTIP1 expression in renal cancer tissues, and the Office of Cancer Clinical Proteomics Research (CPTAC) verified the protein expression of DNTTIP1. Moreover, nomogram predicted the role of DNTTIP1 in ccRCC patient. Single-sample Gene Set Enrichment Analysis (SsGSEA) and GSEA evaluated the pathogenesis role of DNTTIP1 in TCGA-KIRC. Results: DNTTIP1 expression was higher in ccRCC tumor tissues. High expression of DNTTIP1 was associated with poor OS (HR = 1.618, P < 0.0001), and poor DFS (HR = 1.789, P < 0.0001). SsGSEA and GSEA showed DNTTIP1 was associated with hypoxia, epithelial-mesenchymal transition (EMT), angiogenesis, G2M checkpoint. DNTTIP1 had a positive correlation with EMT biomarkers in ccRCC, and might be an effective target for ccRCC. Conclusion: This study provided that higher expression of DNTTIP1 predicted poor prognosis in ccRCC, and DNTTIP1 might be a novel detection biomarker and therapeutic target of tumor malignant in the future. Keywords: DNTTIP1, ccRCC, gene therapy, prognostic indicator Renal cell cancer (RCC) was estimated about 79,000 new cases and 13,920 new deaths in 2022 in the United States, 1 but estimated about 77,410 new cancer cases and 46,345 new deaths in 2022 in China. 2 Histopathologic classifications identified three major subtypes: clear cell RCC (ccRCC; 70–75%), papillary RCC (pRCC; 10–16%), and chromophobe RCC (chRCC; 5%). 3 pRCC occurs sporadically, with several agents including mTOR inhibitors could be used in the treatment of advanced and metastatic pRCC. 4 ChRCCs originated from the intercalated cell of distal tubules, tumor protein P53 and phosphatase and tensin homolog deleted on chromosome ten (PTEN) were the two main frequently mutated genes. 5 CcRCC was the main pathological types, and associated with von Hippel-Lindau (VHL) disease. Loss of function of the VHL tumor suppressor protein (pVHL). 6 pVHL catalyzed the ubiquitination of hypoxia inducible factor (HIF), the degradation of HIFs was inhibited in renal cell carcinoma, 7,8 then increases angiogenesis and tumor metabolism. 9,10 It is of great significance to clarify the potential diagnostic markers and molecular roles in the occurrence and development of ccRCC. Tumor recurrence is still one of the high risks affecting the survival of tumor patients after surgery. 11 Epithelial-mesenchymal transition (EMT), is a characteristic of malignant tumor. 12–14 Inhibition of tumor EMT can slow down tumor metastasis. 15,16 Target of tyrosine kinase inhibitor (TKI) drugs had been discovered for treatment of metastatic ccRCC patients, 17,18 but it still leads to poor progression and recurrence when incomplete reversal of tumor hypoxia and EMT in ccRCC. 19,20 Urgent need to explore new biomarkers or drug targets for ccRCC. The deoxynucleotidyl transferase terminal interacting protein (DNTTIP) plays multiple roles in gene transcr -Abstract Truncated-
pharmacology & pharmacy